Author |
고창순(Chang Soon Koh),이명철(Myung Chul Lee),정준기(June Key Chung),이동수(Dong Soo Lee),김영주(Young Ju Kim),정재민(Jae Min Jeong),장영수(Young Soo Chang), |
Abstract |
The purpose of this study was to examine the
radiolabeling and biodistribution of 188Re(V)-DMSA as a
therapeutic cancer radiopharmaceutical. We made a DMSA
kit(NaHC03 1.5 mg, meso-2,3-dimercaptosuccinic acid 1.0
mg L(+)-ascorbic acid 0.7mg, SnCl2·2H2O 0.34 mg, pH
2.9) for labeling with 188Re. In this kit, 188ReO4- 5
mCi/2 ml added and boiled at 100℃ for 3 hr in water
bath. The final pH adjusted to 7.5 with 7% NaHCO3
solution. We checked the labelling efficacy with TLC-
SG(n-butanol : acetic acid:H2O = 3 : 2 : 3) and
examined the stability both in room temperature and in
serum at 37℃. Biodistribution(l, 3, 13, 24, 48 hr) of
188Re(V)-DMSA compound was evaluated in Sarcoma 180
tumor-bearing mice. Each labeling efficiency and
stability at room temperature for 48 hours was over 98%
and 95%, respectely. The stability in serum were 82%(6
hr) and 85%(48 hr). Tumor uptake of 188Re(V)-DMSA in
Sarcoma 180- bearing mice were 0.66±0.15%(1 hr),
0.51±0.10%(3 hr), 0.19±0..05%(24 hr) and 0.13±0.02%
(48 hr). These result are consistent with those of
99mTc(V)-DMSA which were reported previously In
conclusion, 188Re(V)-DMSA may be a useful therapeutic
radiopharmaceutical for treating some cancers and
metastatic bone lesion. |